Hungarian fund managers have new top pick in October

Richter was the flavour of the month

Hungarys' Richter revises 2019 estimates higher

Management turn more upbeat

Hungary Richter Q3 sales, profit driven by Vraylar sales

Revenue rose 28.2% y/y

Hungary Richter seen reporting record quarterly revenue

Profit expected to jump from low base

Hungary's Richter expects cariprazine to drive growth

Not just in the U.S. but in Europe as well

Hungary's Richter signs license and development agreement with Mycovia

For RVVC drug VT-1161

Richter announces approval in Japan of its licensed-out biosimilar teriparatide

BlackRock stake in Hungary's Richter below 5%

U.S. company informs Richter about decrease on Monday.

Hungary Richter wonderdrug to be distributed in Asia

Mitsubishi Tanabe will distribute cariprazine in Thailand and Singapore.

Hungarian drugmaker Richter projects slight growth in sales this year

With a 10% decrease in Russia and 20% in China

Vraylar sales in U.S. boost Richter Q2 result

Revenue rose 8.5% to HUF 120 billion.

Richter expected to post higher revenue, lower profit in Q2

Analysts forecast 30% lower net profit.

Richter, Hikma sign exclusive license agreement for Cariprazine

Hikma will supply the antipsychotic drug in the MENA region.

Hungarian fund managers have new top pick

Monthly survey results published.

BlackRock voting right in Hungary's Richter under 5.0%

Company informs Hungary's leading pharma co. on Wednesday.

Good news for Richter, share price jumps

Green-light by FDA warmly welcomed.

Hungary's Richter inks exclusive license deal for Australia, New Zealand

Richter to supply, Seqirus to sell.

Hungarian fund managers divided over Mol

Midcaps remain appealing.

Hungary Richter profit leaps in the first quarter of 2019

Revenues and profit overshoot estimates.

Hungary's Richter to report impressive profit growth for Q1

Earnings report to be released on 10 May.